203 related articles for article (PubMed ID: 27749331)
1. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.
Hovelson DH; Tomlins SA
Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
3. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
8. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
9. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
10. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy for castration resistant prostate cancer].
Nasu Y
Nihon Rinsho; 2014 Dec; 72(12):2152-7. PubMed ID: 25518350
[TBL] [Abstract][Full Text] [Related]
14. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotypes of castration-resistant prostate cancer.
Zhang T; Armstrong AJ
Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
[TBL] [Abstract][Full Text] [Related]
18. MiRNA 34a: a therapeutic target for castration-resistant prostate cancer.
Chalanqui MJ; O'Doherty M; Dunne NJ; McCarthy HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1075-85. PubMed ID: 26942553
[TBL] [Abstract][Full Text] [Related]
19. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
20. The impact of recent next generation sequencing and the need for a new classification in gastric cancer.
Businello G; Galuppini F; Fassan M
Best Pract Res Clin Gastroenterol; 2021; 50-51():101730. PubMed ID: 33975684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]